


Ask a doctor about a prescription for COMBIGAN 2 mg/ml + 5 mg/ml EYE DROPS SOLUTION
Package Leaflet: Information for the User
COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution.
Brimonidine tartrate and timolol
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
|
Contents of the pack
COMBIGAN is an eye drop solution that is used to treat glaucoma. It contains two medicines (brimonidine and timolol) that both reduce high pressure in the eye. Brimonidine belongs to a group of medicines called alpha-2 adrenergic receptor agonists. Timolol belongs to a group of medicines called beta-blockers.
COMBIGAN is prescribed to lower high pressure in the eye when using beta-blocker eye drops alone is not enough.
Your eye contains a clear liquid that feeds the inside of the eye. Liquid is constantly being drained from the eye and new liquid is produced to replace it. If the liquid cannot drain out of the eye quickly enough, the pressure inside the eye increases and could harm your sight over time. COMBIGAN works by reducing the production of liquid and increasing the amount of liquid that drains out. This reduces the pressure inside the eye while new liquid is still being produced.
Do not useCOMBIGAN eye drops, solution:
If you think any of these points apply to you, do not use COMBIGAN until you have spoken to your doctor again.
Warnings and precautions
Talk to your doctor before you start using COMBIGAN,
Children and adolescents
COMBIGAN should not be used in children under 2 years of age and is not recommended for use in children and adolescents (from 2 to 17 years of age).
Other medicines and COMBIGAN
COMBIGAN can affect or be affected by other medicines you are using, including other eye drops for treating glaucoma.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines for any other condition, even if they are not related to your eye problem, and even those bought without a prescription.
There are a number of medicines that can interfere with COMBIGAN, so it is very important that you tell your doctor if you are taking:
If you change the dose of any of the medicines you are taking or if you drink alcohol regularly, you should tell your doctor.
If you are going to have an anesthetic, you must tell your doctor or dentist that you are using COMBIGAN.
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Do not use COMBIGAN if you are pregnant unless your doctor considers it necessary.
Do not use COMBIGAN if you are breastfeeding. Timolol can pass into breast milk. Ask your doctor for advice before using any medicine during breastfeeding.
Driving and using machines
COMBIGAN may cause drowsiness, fatigue, or blurred vision in some patients. Do not drive or operate machinery until these symptoms have resolved. If you experience any problems, talk to your doctor.
COMBIGAN contains benzalkonium chloride
This medicine contains 0.25 mg of benzalkonium chloride in each 5 ml of solution, equivalent to 0.05 mg/ml.
Benzalkonium chloride can be absorbed by soft contact lenses, altering their color. Remove contact lenses before using this medicine and wait 15 minutes before putting them back in.
Benzalkonium chloride can cause eye irritation, especially if you have dry eyes or other corneal diseases (diseases of the transparent layer on the front of the eye). Talk to your doctor if you feel any unusual sensation, stinging, or pain in the eye after using this medicine.
COMBIGAN contains phosphates:
This medicine contains 52.9 mg of phosphates in each ml of solution, equivalent to 10.58 mg/ml.
If you have severe corneal damage (the transparent layer on the front of the eye), treatment with phosphates, in very rare cases, can cause blurred vision due to calcium accumulation.
Use this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist. COMBIGAN should not be used in children under 2 years of age and is not recommended for use in children and adolescents (from 2 to 17 years of age).
The recommended dose is one drop of COMBIGAN, twice a day, with a 12-hour interval between doses. Do not change the dose or stop using it without talking to your doctor.
If you use COMBIGAN with other eye drops, wait at least 5 minutes between putting in COMBIGAN and the other eye drops.
Instructions for use
Do not use the container if the security seal is broken when you first open the product.
Wash your hands before opening the container. Tilt your head back and look up at the ceiling.

If the drop falls out of the eye, try again.
To help prevent infections, avoid touching the tip of the container to the eye or any other surface. Close the container immediately after use.
If you use moreCOMBIGANthan you should
Adults
If you use more COMBIGAN than you should, it is unlikely to cause you any harm. Put in the next drop at the usual time. If you are concerned, talk to your doctor or pharmacist.
Babies and children
There have been some cases of overdose in babies and children treated with brimonidine (one of the ingredients of COMBIGAN) as part of their treatment for glaucoma. Symptoms observed include sleepiness, floppiness, low body temperature, paleness, and breathing difficulties. If this happens, contact your doctor immediately.
Adults and children
In case of accidental ingestion, contact your doctor.
In case of overdose or accidental ingestion, talk to your doctor or pharmacist or call the Toxicology Information Service, telephone 91-562 04 20.
If you forget to useCOMBIGAN,
If you forget to use COMBIGAN, use one drop in each eye that needs treatment as soon as you remember, and then go back to your regular routine. Do not take a double dose to make up for forgotten doses.
If you stop usingCOMBIGAN
For COMBIGAN to work properly, you must use it every day.
If you have any further questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you notice any of the following side effects, please contact your doctor immediately:
The following side effects can occur with COMBIGAN
Effects on the eye
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Frequency not known (frequency cannot be estimated from the available data):
Effects on the body:
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Frequency not known (frequency cannot be estimated from the available data):
Some of these effects may be due to an allergic reaction to one of the components of the product.
Additional adverse reactions have been observed with brimonidine or timolol, and therefore may occur with COMBIGAN.
The following adverse reactions have been observed with brimonidine:
As with any other eye medicine, COMBIGAN (brimonidine/timolol) is absorbed into the bloodstream. The absorption of timolol, a beta-blocker component of COMBIGAN, can cause side effects similar to those seen with intravenous and/or oral beta-blockers. The incidence of side effects after topical ophthalmic administration is lower than with oral or injected medicines.
The following side effects have been observed with the use of beta-blockers for the treatment of eye diseases:
Other side effects reported with phosphate-containing eye drops:
If you have severe corneal damage (the transparent layer on the front of the eye), treatment with phosphates, in very rare cases, can cause blurred vision due to calcium accumulation.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store the container in the outer carton to protect it from light.
You should not use more than one container at a time.
Do not use this medicine after the expiry date which is stated on the carton and on the container after EXP. The expiry date is the last day of the month stated.
You should throw away the container 4 weeks after you first open it, even if there are still some drops left. This will help prevent infections. To help you remember, write the date you opened it on the space provided on the carton.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
COMBIGAN composition
Appearance of COMBIGAN and container contents
COMBIGAN is a clear, slightly yellow-green eye drop solution in a plastic container with a screw cap. Each container is filled to approximately half and contains 5 ml of solution. Boxes are available containing 1 or 3 containers. Only some container sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
AbbVie Spain, S.L.U.
Avenida de Burgos 91,
28050 Madrid
Spain
Manufacturer:
Allergan Pharmaceuticals Ireland
Castlebar Road
Westport, Co Mayo
Ireland
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Austria | Combigan 2 mg/ml + 5 mg/ml eye drops |
Belgium | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Bulgaria | ???????? 2 mg/ml + 5 mg/ml ????? ?? ???, ??????? Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Czech Republic | COMBIGAN 2mg/ml + 5 mg/ml eye drops, solution |
Croatia | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Denmark | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Estonia | Combigan, 2 mg/5 mg/ml eye drops, solution |
Finland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
France | COMBIGAN 2 mg/ml + 5 mg/ml, eye drops in solution |
Germany | Combigan 2 mg/ml + 5 mg/ml eye drops |
Greece | COMBIGAN οφθαλμικ?ς σταγ?νες, δι?λυμα, (0,2 + 0,5)% |
Hungary | COMBIGAN 2 mg/ml+5 mg/ml eye drops, solution |
Iceland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Ireland | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Italy | COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution |
Latvia | Combigan2 mg/5 mg/ml eye drops, solution |
Lithuania | Combigan 2 mg/5 mg/ml eye drops, solution |
Luxembourg | Combigan 2 mg/ml + 5 mg/ml, eye drops in solution |
Netherlands | Combigan 2 mg/ml + 5 mg/ml, eye drops, solution |
Norway | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Poland | Combigan eye drops, solution, 2 mg/ml + 5 mg/ml |
Portugal | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Romania | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Slovakia | COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution |
Slovenia | COMBIGAN 2 mg/ml + 5 mg/ml eye drops, solution |
Spain | Combigan 2mg/ml + 5 mg/ml eye drops in solution |
Sweden | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
United Kingdom | Combigan 2 mg/ml + 5 mg/ml eye drops, solution |
Date of last revision of this leaflet: 11/2020
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of COMBIGAN 2 mg/ml + 5 mg/ml EYE DROPS SOLUTION in November, 2025 is around 15.67 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for COMBIGAN 2 mg/ml + 5 mg/ml EYE DROPS SOLUTION – subject to medical assessment and local rules.